Savant Capital LLC Boosts Stake in United Therapeutics Co. (NASDAQ:UTHR)

Savant Capital LLC raised its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 2.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,205 shares of the biotechnology company’s stock after buying an additional 266 shares during the quarter. Savant Capital LLC’s holdings in United Therapeutics were worth $3,601,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Milestone Asset Management LLC grew its holdings in shares of United Therapeutics by 56.5% in the fourth quarter. Milestone Asset Management LLC now owns 2,874 shares of the biotechnology company’s stock valued at $1,014,000 after purchasing an additional 1,037 shares in the last quarter. Janney Montgomery Scott LLC lifted its position in United Therapeutics by 9.1% during the fourth quarter. Janney Montgomery Scott LLC now owns 9,427 shares of the biotechnology company’s stock valued at $3,326,000 after purchasing an additional 789 shares during the last quarter. JPMorgan Chase & Co. lifted its position in United Therapeutics by 35.4% during the third quarter. JPMorgan Chase & Co. now owns 192,546 shares of the biotechnology company’s stock valued at $68,999,000 after purchasing an additional 50,291 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of United Therapeutics by 97.7% in the 3rd quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock worth $89,532,000 after buying an additional 123,929 shares in the last quarter. Finally, Burney Co. increased its holdings in shares of United Therapeutics by 113.3% in the 4th quarter. Burney Co. now owns 23,922 shares of the biotechnology company’s stock worth $8,441,000 after buying an additional 12,705 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on UTHR. TD Cowen increased their price target on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, October 21st. Argus raised their price objective on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Oppenheimer boosted their target price on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. UBS Group raised their price target on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Finally, The Goldman Sachs Group lifted their price objective on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $382.08.

Insiders Place Their Bets

In other United Therapeutics news, EVP Paul A. Mahon sold 7,700 shares of the firm’s stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $374.37, for a total transaction of $2,882,649.00. Following the transaction, the executive vice president now owns 36,710 shares of the company’s stock, valued at approximately $13,743,122.70. This trade represents a 17.34 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $348.06, for a total transaction of $3,480,600.00. Following the completion of the sale, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at $896,950.62. The trade was a 79.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 121,864 shares of company stock worth $44,516,965 in the last three months. Corporate insiders own 11.90% of the company’s stock.

United Therapeutics Trading Up 2.2 %

NASDAQ UTHR opened at $353.31 on Wednesday. United Therapeutics Co. has a 12 month low of $210.64 and a 12 month high of $417.82. The company’s 50-day moving average price is $362.06 and its 200-day moving average price is $358.24. The stock has a market cap of $15.78 billion, a PE ratio of 15.52, a PEG ratio of 0.92 and a beta of 0.57.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.